ZFIN ID: ZDB-FISH-150901-3737
Fish name: WT + MO2-rps19
Genotype: WT
Targeting Reagent: MO2-rps19
HUMAN DISEASE MODELED by WT + MO2-rps19
Human Disease Conditions Citations
Diamond-Blackfan anemia control (2)
GENE EXPRESSION
Gene expression in WT + MO2-rps19
RNA expression
Expressed Gene Structure Conditions Figures
ada standard conditions Fig. 4 from Danilova et al., 2008
baxa standard conditions Fig. 4 from Danilova et al., 2008
cdkn1a standard conditions Fig. 4 from Danilova et al., 2008
gata2a standard conditions Fig. 5 from Danilova et al., 2008
gsc standard conditions Fig. 5 from Danilova et al., 2008
hbae1.1 standard conditions Fig. 3 from Danilova et al., 2008
ins standard conditions Fig. 2 from Danilova et al., 2008
lft2 standard conditions Fig. 2 from Danilova et al., 2008
tp53 standard conditions Fig. 4 from Danilova et al., 2008
tp63 standard conditions Fig. 4Fig. 5 from Danilova et al., 2008
tp73 standard conditions Fig. 4 from Danilova et al., 2008
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in WT + MO2-rps19
Phenotype Conditions Figures
blood apoptotic process increased process quality, abnormal standard conditions Fig. 6 with image from Danilova et al., 2014
brain necrotic, abnormal standard conditions Fig. 2 from Danilova et al., 2008
cranial cartilage malformed, abnormal standard conditions Fig. 2 from Danilova et al., 2008
digestive system position, abnormal standard conditions Fig. 2 from Danilova et al., 2008
erythrocyte development disrupted, abnormal standard conditions Fig. 3 from Danilova et al., 2008
erythrocyte differentiation decreased occurrence, abnormal control Fig. 4 from Bibikova et al., 2014
erythrocyte differentiation occurrence, normal chemical treatment: pharmaceutical Fig. 4 from Bibikova et al., 2014
eye aplastic, abnormal standard conditions Fig. 2 from Danilova et al., 2008
eye decreased size, abnormal standard conditions Fig. 2 from Danilova et al., 2008
eye hypoplastic, abnormal control Fig. 4 from Bibikova et al., 2014
forebrain aplastic, abnormal standard conditions Fig. 2 from Danilova et al., 2008
forebrain decreased size, abnormal standard conditions Fig. 2 from Danilova et al., 2008
head decreased size, abnormal standard conditions Fig. 2 from Danilova et al., 2008
head apoptotic process increased process quality, abnormal standard conditions Fig. 6 with image from Danilova et al., 2014
heart primordium position, abnormal standard conditions Fig. 2 from Danilova et al., 2008
intermediate cell mass of mesoderm erythroblast increased amount, abnormal standard conditions Fig. 3 from Danilova et al., 2008
midbrain hindbrain boundary malformed, abnormal standard conditions Fig. 2 from Danilova et al., 2008
nucleate erythrocyte decreased amount, abnormal standard conditions Fig. 3 with image from Danilova et al., 2014
Fig. 3 from Danilova et al., 2008
optic primordium decreased size, abnormal standard conditions Fig. 2 from Danilova et al., 2008
whole organism apoptotic, abnormal standard conditions Fig. 2 from Danilova et al., 2008
whole organism decreased size, abnormal control Fig. 4 from Bibikova et al., 2014
whole organism morphology, abnormal control Fig. 4 from Bibikova et al., 2014
whole organism morphology, normal chemical treatment: pharmaceutical Fig. 4 from Bibikova et al., 2014
whole organism anterior-posterior axis curved, abnormal control Fig. 4 from Bibikova et al., 2014
whole organism anterior-posterior axis kinked, abnormal control Fig. 4 from Bibikova et al., 2014
whole organism ribosome decreased amount, abnormal standard conditions Fig. 1 from Danilova et al., 2008

CITATIONS  (4)